Core Viewpoint - Vesicor Therapeutics, Inc. has appointed Dr. Michael Tolentino as the new CEO, succeeding founder Dr. Luo Feng, as the company aims to advance its p53-based cancer therapeutics and complete a proposed de-SPAC merger with Black Hawk Acquisition Corporation [1][2]. Company Overview - Vesicor Therapeutics is an early development stage biotechnology company based in San Gabriel, California, focusing on p53-based cancer therapeutics delivered via precision-engineered microvesicles [1]. - The company is in the process of a proposed merger with Black Hawk Acquisition Corporation, a SPAC, to accelerate its development efforts [2]. Leadership Appointment - Dr. Michael Tolentino brings over 20 years of experience in the biotechnology sector and has a proven track record in drug discovery and development [3]. - His previous roles include significant contributions to the development of Avastin and Bevasiranib, showcasing his expertise in both pre-clinical and clinical development [3][4]. Strategic Goals - Dr. Tolentino expressed his commitment to building upon Vesicor's technology and aims for an Investigational New Drug (IND) submission to the FDA by 2027 [2]. - The company is focused on developing potent cancer therapeutics and creating shareholder value through its innovative approaches [2]. Financial and Development Background - Dr. Tolentino has a history of successful ventures, including the sale of Promedior, Inc. to Roche for $390 million, with potential contingent payments up to $1 billion [4]. - He has co-founded multiple biotechnology companies, including Aviceda Therapeutics, which secured $207.5 million in Series C financing [6]. Research and Development Focus - Vesicor's therapeutic approach involves using microvesicles to deliver cancer-targeting agents, including p53 gene delivery and other chemotherapeutics [9]. - The company aims to leverage advanced technologies and collaborations to enhance its drug development pipeline [8].
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer